×
About 15,915 results

Lung Screening Saves Lives; Clues to Hyperprogression; Bacteria Foil Immunotherapy
https://www.medpagetoday.com/hematologyoncology/lungcancer/101912

Nov 25th, 2022 - Diagnosis of early-stage lung cancer with low-dose CT screening was associated with significant improvement in long-term survival. (Mount Sinai, Radiological Society of North America) Researchers have discovered how cancer immunotherapy sometimes causes paradoxical tumor hyperprogression and identified a potential mechanism to prevent it. (Science Translational Medicine) Continuing its expansio...

More Racial Cancer Disparities; Potential Pharma Bankruptcy; HPV Vax Efficacy
https://www.medpagetoday.com/hematologyoncology/othercancers/101676

Nov 10th, 2022 - American Indian and Alaska Native individuals have a substantially higher cancer mortality despite cancer incidence similar to other racial/ethnic groups in the U.S. (American Cancer Society) Non-Hispanic Black patients were less likely to receive complete guideline-recommended care for ovarian cancer even after adjustment for access-to-care issues. (National Comprehensive Cancer Network) A lay...

Novel Co-Admin of CAR T Cells Achieves 99% Remission in Leukemia
https://www.medscape.com/viewarticle/983714

Nov 8th, 2022 - A novel approach in which two products were co-administered achieved a 99% complete response rate in children with relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (B-ALL). In this trial, the largest study to date of a CAR T-cell therapy for such patients, the researchers co-administered two CAR T-cell therapies, one targeting CD19 and the other targeting CD22. The results sh...

Call for Resistance to E-Cigs; Optimal Timing of ADT; Include Diet in Cancer Therapy
https://www.medpagetoday.com/hematologyoncology/othercancers/101479

Oct 28th, 2022 - The American Association for Cancer Research and the American Society of Clinical Oncology adopted a joint policy statement calling for continued policy and regulatory efforts to combat the use of electronic nicotine delivery systems (ENDS), such as e-cigarettes, as well as support for research into the health effects of ENDS. The FDA issued marketing denial orders for Logic Technology Developm...

Duvelisib Loses Support for CLL/SLL Indication Following ODAC Meeting
https://www.onclive.com/view/duvelisib-loses-support-for-cll-sll-indication-following-odac-meeting

Oct 24th, 2022 - In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the final overall survival (OS) data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib (Copiktra) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies.1 Top concerns addr...

ASTX727/Venetoclax Combo Is Safe and Effective in First-Line and Relapsed/Refractory AML
https://www.onclive.com/view/astx727-venetoclax-combo-is-safe-and-effective-in-first-line-and-relapsed-refractory-aml

Oct 24th, 2022 - Oral decitabine plus cedazuridine (ASTX727) added to oral venetoclax (Venclexta) demonstrated promising overall response rates in patients with acute myeloid leukemia (AML) who received the combination as a first-line treatment or after relapsing on prior therapies, according to findings from a phase 2 study (NCT04746235) presented at the 10th Annual Meeting of the Society of Hematologic Oncolo...

Meningioma Risk After Cranial Radiotherapy for Childhood Cancer
https://www.medscape.com/viewarticle/982540

Oct 17th, 2022 - Children who received cranial radiotherapy to treat their cancer faced an increased risk of developing meningioma — the most common type of benign brain tumor — decades after being exposed, according to a recent analysis. More specifically, among pediatric cancer survivors exposed to cranial radiation, those who received doses above 24 Gy had more than 30-fold higher odds of meningioma, and thi...

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03739814

Oct 14th, 2022 - PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen of inotuzumab ozogamicin followed by blinatumomab. II. To estimate the 1-year event-free survival of older, transplant-ineligible patients with newly diagnosed, Philadelphia (Ph)-negative, CD22-positive, B-cell acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin induction followed by blinatumomab consoli...

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
https://clinicaltrials.gov/ct2/show/NCT02828358

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-R). SECONDARY OBJECTIVE: I. To evaluate the biologic activity of azacitidine by pharmacodynamic assessment of global deoxyribonucleic acid (DNA) methylation in peripheral blood ...

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04639843

Oct 14th, 2022 - Background: T-cell lymphomas (TCLs) are a heterogeneous group of lymphoid malignancies defined by clonal proliferation of post-thymic T lymphocytes. Patients with newly diagnosed TCLs are most commonly treated with a CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)-like regimen, with less than 30% having durable complete responses (CRs). Of the chemotherapy agents used, doxorubi...

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation
https://clinicaltrials.gov/ct2/show/NCT04781855

Oct 14th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ipilimumab in combination with ibrutinib in patients with CLL/small lymphocytic lymphoma (SLL)/RT. (Part A) II. To determine the MTD and DLT of ipilimumab in combination with nivolumab and ibrutinib in patients with CLL/SLL/RT. (Part B) SECONDARY OBJECTIVES: I. To determine the efficacy (res...

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT04774393

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety and tolerability and recommended phase 2 dose (RP2D) of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with either ivosidenib (Arm A) or enasidenib (Arm B) for patients with acute myeloid leukemia. (Phase Ib) II. To determine the overall response rate (complete response [CR], complete remission with incomplete hematologic recov...

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Oct 14th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biology (LMB). HCL variants often resemble classic HCL but are more aggressive and less responsive to treatments, such as HCLv and IGHV4-34+ HCL that are im...

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell T...
https://clinicaltrials.gov/ct2/show/NCT01087294

Oct 14th, 2022 - Background: Many patients with advanced B-cell malignancies that cannot be cured by chemotherapy and monoclonal antibodies have prolonged relapse-free survival after allogeneic hematopoietic stem cell transplantation (alloHSCT); however, a substantial fraction of patients with B-cell malignancies relapse following alloHSCT. The first therapeutic maneuver attempted when patients without graft-ve...

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02756897

Oct 14th, 2022 - PRIMARY OBJECTIVE: I. Estimate therapeutic activity (best response [complete response (CR)/complete response with incomplete recovery (CRi)]) of combined ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL). SECONDARY OBJECTIVES: I. To determine the safety of this combination strategy. II. To estimate the time to best response with this c...

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02675452

Oct 14th, 2022 - This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia The study will be conducted in five parts.

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Oct 14th, 2022 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventions, significant numbers of pediatric cancer patients develop recurrent and resistant disease. Targeting the tumor microenvironment is a promising but...

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymp...
https://clinicaltrials.gov/ct2/show/NCT04994717

Oct 14th, 2022 - The safety run-in part of the study aims to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy. The phase 3 part of the study aims to compare event-free survival (EFS) and overall survival (OS) of participants receiving blinatumomab alternating with low-intensity chemotherapy to EFS and (OS) of participants receiving standard of care (SOC) chemother...

Natural Killer Cells and Bortezomib to Treat Cancer
https://clinicaltrials.gov/ct2/show/NCT00720785

Oct 14th, 2022 - Natural killer (NK) cells are innate immune lymphocytes that are identified by the expression of the CD56 surface antigen and the lack of CD3. Unlike antigen specific T cells, NK cells do not require the presence of a specific tumor antigen for the recognition and killing of cancer cells. Our in vitro studies have demonstrated that pretreatment of malignant cells with bortezomib significantly e...

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT03914625

Oct 14th, 2022 - PRIMARY OBJECTIVES: I. To determine in a randomized manner if the addition of 2 cycles of blinatumomab to standard therapy improves disease-free survival (DFS) in patients with standard risk (SR) B-ALL and higher risk features (SR-High), and patients with standard-risk average (SR-Avg) B-ALL who are negative for minimal residual disease (MRD) by flow cytometry but have detectable or indetermina...